Delineating breast cancer subtypes based on biomarkers. Image © iQoncept/Shutterstock.com
FDA Approves Atezolizumab for Refractory Metastatic Non-Small Cell Lung Cancer
The US Food and Drug Administration (FDA) has approved atezolizumab (Tecentriq®, Genentech) for treating chemotherapy-refractory, metastatic non-small cell lung cancer (NSCLC), Genentech announced.
Transplant May Still Benefit CML Patients Experiencing TKI Resistance
When CML patients develop resistance or intolerance to these drugs, transplant may be the only option.
Nasal Tumor Found in 46-Year-Old Man
A 46-year-old man is found to have a nasal tumor. After further assessment, a biopsy is performed. What is your diagnosis?
ESMO 2016: Anti-PD-1 Therapy for Cisplatin Ineligible Bladder Cancer Patients
New immunotherapies that target PD-1 are now showing promise for first-line and second-line treatment of metastatic bladder cancer.
ESMO 2016: Early Results for Pembrolizumab Against Metastatic Enzalutamide-Refractory Prostate Cancer
Pembrolizumab showed clinical activity against some cases of enzalutamide-refractory metastatic castration-resistant prostate cancer.
ESMO 2016: Slow-Growing Melanomas Are More Sensitive to Pembrolizumab, Nivolumab
Objective tumor responses to pembrolizumab (Keytruda) and nivolumab (Opdivo) are associated with longer times between melanoma diagnosis and treatment.
ESMO 2016: Pembrolizumab Bests Chemotherapy for First-Line Lung Cancer Treatment
Adding pembrolizumab (Keytruda) to first-line chemotherapy improves response and survival rates among patients with previously-untreated advanced PD-L1-positive non-small cell lung cancer.
Better Research Efforts Needed Among Racial/Ethnic Population
Dr. Bobby Lazzara highlights a recent study published in JAMA Oncology on ethnic/racial disparity in genome sequencing and how researchers may be leaving this population behind.
The Illinois Precision Medicine Initiative Cohort Program to Enroll Participants
The University of Illinois at Chicago, Northwestern University, the University of Chicago, and other affiliated hospitals and clinics have been selected to enroll 150,000 Illinoisans in the national Precision Medicine Initiative Cohort Program.
Shorter Turnaround Time for BRAF Mutation Testing
Obtaining blood biopsies instead of invasive tissue biopsies may be less risky for patients, faster, and cost less.
March 2016 News Recap
In case you missed it, check out our March recap featuring some of the latest in clinical trial news, a new indication for Afinitor, how genetics affect prognosis, and more.
Epidermal Growth Factor Receptor Inhibitor Cutaneous Side Effects
This slide show highlights some of the cutaneous side effects related to the use of epidermal growth factor receptor inhibitors (EGFRI).
Slide Show: Highlights From the 2015 ASCO Breast Cancer Symposium
This slide show highlights some of the presentations that took place at the 2015 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium in San Francisco, September 25-27, 2015.
Slide Show: Trends in Targeted Therapies and Immunotherapies
This slide show provides information on the present and future of targeted therapies and immunotherapies based on a report from the IMS Institute for Healthcare Informatics.
By clicking Accept, you agree to become a member of the UBM Medica Community.